PiverS.M., SharadA.Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel and platinum resistant advanced ovarian cancer.Proc ASCO, 18: 1478 (abst), 1999.
2.
LestingiT.M., DolanJ.R., YordanE.L.Jr.A phase I/II evaluation of escalating dose topotecan and cisplatin in recurrent, platinum sensitive ovarian cancer.Proc ASCO, 19: 1542 (abst), 2000.
3.
TrudeauM., LanglebenA., Burdette-RadouxS.Topotecan and cisplatin is an active regimen in relapsing ovarian cancer: a pilot experience.Proc ASCO, 18: 1489 (abst), 1999.
4.
FullerA.F.Jr., PensonR.T., SupkoJ.G.A phase I/II and pharmacokinetic study of 96-hour infusional topotecan and paclitaxel chemotherapy for recurrent Müllerian tumors.Proc ASCO, 19: 1552 (abst), 2000.
5.
LeeR.T., SmithD., WertheimI.Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.Proc ASCO, 19: 1608 (abst), 2000.
6.
O’ ReillyS., FlemingG.F., BakerS.D.Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group Study.J Clin Oncol, 15: 177–186, 1997.
7.
PensonR.T., SupkoJ.G., CookS.E.A phase I/II and pharmacokinetic study of 96 hour infusional topotecan and paclitaxel chemotherapy for relapsed epithelial ovarian cancer.Proc ASCO, 18: 1477 (abst), 1999.
8.
LedermannJ.A., HerdR., MaraninchiP.High dose chemotherapy in ovarian cancer. An analysis of the experience of the European Group for Blood and Marrow Transplant (EBMT) over 7 years.Proc ASCO18: 1391 (abst), 1999.
9.
DistefanoM., FerliniC., De VincenzoR.: Antagonistic effect of the combination gemcitabine topotecan in ovarian cancer cells.Cancer Chemother Pharmacol (submitted for publication).
10.
RubinS.C., RandallT.C., ArmstrongK.A.Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings.Obstet Gynecol, 93: 21–24, 1999.
11.
LambertH.E., RustinG.J., GregoryW.M.A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study.Ann Oncol, 8: 327–333, 1997.
12.
HakesT.B., ChalasE., HoskinsW.J.Randomized prospective trial of 5 versus 10 cyles of cyclophosphamide, doxorubicin and cisplatin in advanced ovarian carcinoma.Gynecologic Oncology, 45: 284–289, 1992.
13.
BertelsenK., JakobsenA., StroyerI.A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group Trial (DACOVA).Gynecol Oncol, 49: 30–36, 1993.
McGuireW.P., BlessingJ.A., BookmanM.A.Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study.J Clin Oncol, 18: 1062–1067, 2000.
16.
ScarfoneG., BolisG., VillaA.Phase I-II sequential topotecan (TPT) chemotherapy in patients (PTS) with small residual disease (SRD) after taxol-carboplatin (TC) as first line chemotherapy in advanced epithelial ovarian cancer (AEOC).Proc ASCO, 17: 1396 (abst), 1998.
17.
ChanS., CarmichelJ., RossG.Sequential hycamptin following paclitaxel and carboplatin in advanced ovarian cancer.Proc ASCO, 18: 1436 (abst), 1999.
18.
PignataS., Di VagnoG., BiancoA.Topotecan vs nihil following response to carboplatin + paclitaxel in advanced ovarian cancer (AOC). Early data on compliance and toxicity of topotecan from the MITO (Multicenter Italian Trials in Ovarian Cancer) Study.Proc ASCO, 19: 1619 (abst), 2000.
